A MEDICAL firm behind custom prescriptions has received approval for a new product it says could save the NHS millions of pounds.

Quantum Pharma says its Biodose Connect device has received the backing of the UK healthcare regulator.

Bosses say Biodose works remotely by monitoring if a patient is taking medicines as prescribed.

They added it could play a crucial role in reducing waste, with reports claiming the value of medicines not taken for long-term conditions amounts to about £100m every year.

Quantum says it will now take its device to the commercial stage, adding it will be branded as Biodose Connect by Vaica.

The business has worked with Vaica Medical on the equipment since late 2014.

Andrew Scaife, chief executive at Quantum, which is based at Burnopfield, near Stanley, County Durham, said: “Biodose Connect is an exciting product we believe will provide a huge benefit to the NHS, social care providers and pharmaceutical companies, not only by reducing the burden created by medication non-adherence, but also in allowing patients to be treated at home.

“We look forward to bringing Biodose Connect to the market and showcasing its strong benefits.”

Quantum employs about 250 people and has a vast programme of more than 30,000 drugs, including its Mucodis brand, which includes a spray and mouthwash to help ease patients’ well-being post cancer care.

Supplying medicines for unique prescriptions, its staff alter drugs’ potencies, assess ingredients to counter allergies and change distribution from tablet to liquid form.